| pubmed-article:17700285 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17700285 | lifeskim:mentions | umls-concept:C1533685 | lld:lifeskim |
| pubmed-article:17700285 | lifeskim:mentions | umls-concept:C0796392 | lld:lifeskim |
| pubmed-article:17700285 | lifeskim:mentions | umls-concept:C0017609 | lld:lifeskim |
| pubmed-article:17700285 | lifeskim:mentions | umls-concept:C1517572 | lld:lifeskim |
| pubmed-article:17700285 | lifeskim:mentions | umls-concept:C1656863 | lld:lifeskim |
| pubmed-article:17700285 | lifeskim:mentions | umls-concept:C1135130 | lld:lifeskim |
| pubmed-article:17700285 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17700285 | pubmed:dateCreated | 2007-8-16 | lld:pubmed |
| pubmed-article:17700285 | pubmed:abstractText | Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion who received treatment with intravitreal bevacizumab (Avastin) a nonselective antibody against vascular endothelial growth factor-A. Both patients demonstrated dramatic short-term response in terms of intraocular pressure reduction and regression of neovascularization. | lld:pubmed |
| pubmed-article:17700285 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17700285 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17700285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17700285 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17700285 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:17700285 | pubmed:issn | 1057-0829 | lld:pubmed |
| pubmed-article:17700285 | pubmed:author | pubmed-author:YazdaniShahin... | lld:pubmed |
| pubmed-article:17700285 | pubmed:author | pubmed-author:PakravanMoham... | lld:pubmed |
| pubmed-article:17700285 | pubmed:author | pubmed-author:HendiKamranK | lld:pubmed |
| pubmed-article:17700285 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17700285 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:17700285 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17700285 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17700285 | pubmed:pagination | 437-9 | lld:pubmed |
| pubmed-article:17700285 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:meshHeading | pubmed-meshheading:17700285... | lld:pubmed |
| pubmed-article:17700285 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17700285 | pubmed:articleTitle | Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. | lld:pubmed |
| pubmed-article:17700285 | pubmed:affiliation | Ophthalmic Research Center and Department of Ophthalmology, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Tehran, Iran. shahinyazdani@yahoo.com | lld:pubmed |
| pubmed-article:17700285 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17700285 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700285 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700285 | lld:pubmed |
